PROSCA 2023 Satellite Symposium: Professor Nazareno Suardi
In this Satellite symposium recorded from PROSCA 2023, Professor Nazareno Suardi (Associate Professor of Urology – Università di Brescia, Italy) discusses how to manage Androgen Deprivation Therapy (ADT) when a patient has a cardiovascular risk
As part of the video below, Professor Nazareno walk through the following topics:
- Cardiovascular risk in Luteinizing hormone-releasing hormone (LHRH) agonists vs antagonists4
- Associated cardiovascular adverse events5
- Recommendations for adverse events risk assessment and monitoring during ADT therapy for prostate cancer6
- HERO Phase III Trial results7
Watch video below
Duration : 05:15 min
Professor Nazareno Suardi
Nazareno Suardi attended both the Medical School and the Residency program in Urology at the University Vita-Salute San Raffaele in Milan, Italy. He completed a research fellowship at the Cancer Prognostics and Health Outcomes Unit at the University of Montreal, Canada, and a clinical fellowship in robotic urologic surgery at the OLV Clinic in Aalst, Belgium. Dr. Suardi covered the position of staff urologist at the Department of Urology of the Vita-Salute University San Raffaele from 2008 to 2019, after which he became Associate Professor of Urology at the University of Genoa.
Since 2021 he is Associate Professor of Urology at the University of Brescia in Italy. He is currently the Director of the Urological Department of the Spedali Civili Hospital in Brescia. His major field of interest is urological oncology, with special attention to the diagnosis and treatment of prostate cancer.
Orgovyx® is the One & Only Oral ADT indicated for the treatment of:1-3
- Adult patients with advanced hormone -sensitive prostate cancer
- High-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy
- High-risk localised or locally advanced hormone dependent prostate cancer as a neo-adjuvant treatment prior to radiotherapy
References:
- ORGOVYX® Summary of Product Characteristics
- Fragkoulis C, et al. Arab Journal of Urology. 2021; 19(4):460-463
- National Institute for Health and Care Excellence. British National Formulary. Available from: https://bnf.nice.org.uk/drugs. Accessed: September 2024
- Mytilecas, et al. Investigative and Clinical Urology. 2023; 65:572-578
- Albertsen P C, et al. European Urology. 2014;65:565-73
- Lyon A R, et al. European Heart Journal. 2022; 43(41):4229-4361
- Shore N D, et al. New England Journal of Medicine. 2020; 382(23):2187-2196
Related Content
